John P. Leonard, MD, Weill Cornell Medicine

Treatment of R/R DLBCL: CD19-Directed Therapy vs CAR T

July 15th 2020

CD19-Directed Therapies for Treatment of R/R DLBCL

July 15th 2020

CAR T in R/R DLBCL: Safety and Patient Selection

July 15th 2020

ASCO 2020 Data: CAR T in R/R DLBCL

July 15th 2020

Role of CAR T-cell Therapy in R/R DLBCL

July 15th 2020

Treatment in Transplant-ineligible R/R DLBCL

July 15th 2020

Prognosis of R/R DLBCL

July 15th 2020

Standard of Care for Treatment of DLBCL

July 15th 2020

Dr. Leonard on the FDA Approval of Tazemetostat in Follicular Lymphoma

June 18th 2020

John P. Leonard, MD, discusses the FDA approval of tazemetostat in follicular lymphoma.

Dr. Leonard on AUGMENT Trial Results in Non-Hodgkin Lymphoma

December 3rd 2018

John P. Leonard, MD, associate dean for clinical research and Richard T. Silver Distinguished Professor of Hematology and Medical Oncology, Meyer Cancer Center, Weill Cornell Medicine and New York Presbyterian Hospital, discusses the key takeaway from the phase III AUGMENT trial, a randomized study of lenalidomide (Revlimid) plus rituximab (Rituxan) (R2) versus rituximab/placebo in patients with relapsed/refractory indolent non-Hodgkin lymphoma, during the 2018 ASH Annual Meeting.

Dr. Leonard on Precision Medicine in Hematologic Malignancies

August 24th 2017

John P. Leonard, MD, associate dean of Clinical Research, interim chair of the Department of Medicine, Weill Cornell Medical College, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the advance of precision medicine across hematologic malignancies.

Dr. Leonard on Exciting Advancements in the Field of Mantle Cell Lymphoma

August 7th 2017

John P. Leonard, MD, professor of Medicine at Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses some of the exciting advancements taking place in the field of mantle cell lymphoma (MCL).

Dr. Leonard on Rituximab Maintenance Strategy for Patients With MCL

May 15th 2017

John P. Leonard, MD, professor of medicine at Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the maintenance strategy of rituximab (Rituxan) for patients with mantle cell lymphoma (MCL).

Dr. Leonard on Emergence of CAR T-cell Therapy in Hematologic Cancers

May 5th 2017

John P. Leonard, MD, associate dean of Clinical Research, interim chair of the Department of Medicine, Weill Cornell Medical College, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the emergence and potential of chimeric antigen receptor (CAR) T-cell therapy across hematologic malignancies.

Dr. Leonard on Treating Relapsed Patients With Follicular Lymphoma

May 12th 2016

John P. Leonard, MD, medical oncology, Weill Cornell Medicine and New-York Presbyterian, discusses treatment considerations for relapsed patients with follicular lymphoma.

Dr. Leonard on Treatment Options for Patients With Indolent B-Cell NHL

November 16th 2015

John P. Leonard, MD, medical oncology, NewYork-Presbyterian Hospital/Weill Cornell Medical Center, discusses therapies available for patients with indolent B-cell Non-Hodgkin lymphoma.

Dr. Leonard on Ibrutinib Combined With Chemotherapy in Follicular Lymphoma

August 20th 2015

John P. Leonard, MD, medical oncology, NewYork-Presbyterian Hospital/Weill Cornell Medical Center, discusses the phase III SELENE study, which is examining the addition of ibrutinib to either R-CHOP or bendamustine plus rituximab for the treatment of patients with follicular lymphoma.

Dr. Leonard on Lenalidomide With Rituximab in Follicular Lymphoma

June 24th 2015

John P. Leonard, MD, medical oncology, NewYork-Presbyterian Hospital/Weill Cornell Medical Center, discusses an ongoing study examining the use of lenalidomide combined with rituximab in patients with recurrent follicular lymphoma.